This topic contains 0 replies, has 1 voice, and was last updated by  MS News Today Moderator 1 month, 3 weeks ago.

  • Author
    Posts
  • #18297
     MS News Today Moderator 
    Participant

    Two years after its approval and with new data from ECTRIMS, Ocrevus is living up to its designation as a “game-changer,” Genentech’s Hideki Garren says. Read more here.

    Do you agree that Ocrevus is a “game-changer” for people with MS?

You must be logged in to reply to this topic.

Copyright © 2017-2019 All rights reserved.

©2019 KLEO Template a premium and multipurpose theme from Seventh Queen

CONTACT US

We're not around right now. But you can send us an email and we'll get back to you, asap.

Sending
or

Log in with your credentials

or    

Forgot your details?

or

Create Account